Keisuke Otani
YOU?
Author Swipe
View article: Androgen receptor splice variant expression and prostate cancer recurrence after salvage therapy
Androgen receptor splice variant expression and prostate cancer recurrence after salvage therapy Open
Prostate cancer is driven by androgen receptor (AR) signaling, and radiotherapy (RT) with or without androgen deprivation therapy (ADT) offers a second opportunity at cure for men with local or biochemical recurrence after prostatectomy. I…
View article: Tumor cell-based liquid biopsy using high-throughput microfluidic enrichment of entire leukapheresis product
Tumor cell-based liquid biopsy using high-throughput microfluidic enrichment of entire leukapheresis product Open
Circulating Tumor Cells (CTCs) in blood encompass DNA, RNA, and protein biomarkers, but clinical utility is limited by their rarity. To enable tumor epitope-agnostic interrogation of large blood volumes, we developed a high-throughput micr…
View article: Tumor cell-based liquid biopsy using high-throughput microfluidic enrichment of entire leukapheresis product
Tumor cell-based liquid biopsy using high-throughput microfluidic enrichment of entire leukapheresis product Open
Circulating Tumor Cells (CTCs), interrogated by sampling blood from patients with cancer, contain multiple analytes, including intact RNA, high molecular weight DNA, proteins, and metabolic markers. However, the clinical utility of tumor c…
View article: Circulating and Imaging Biomarkers of Radium-223 Response in Metastatic Castration-Resistant Prostate Cancer
Circulating and Imaging Biomarkers of Radium-223 Response in Metastatic Castration-Resistant Prostate Cancer Open
PURPOSE Radium-223 improves overall survival (OS) and reduces skeletal events in patients with bone metastatic castration-resistant prostate cancer (CRPC), but relevant biomarkers are lacking. We evaluated automated bone scan index (aBSI) …
View article: Data from Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer
Data from Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer Open
Purpose:There is an urgent need for biomarkers of radiation response in organ-sparing therapies. Bladder preservation with trimodality therapy (TMT), consisting of transurethral tumor resection followed by chemoradiation, is an alternative…
View article: Supplementary Figure S12 from Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer
Supplementary Figure S12 from Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer Open
DDR Mutations and association with re-modified BI-EFS.
View article: Supplementary Figure S10 from Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer
Supplementary Figure S10 from Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer Open
Comparison of Patient Eligibility based on select DNA Damage Response (DDR) gene mutations for the Alliance A031701, RETAIN-BLADDER Trials and by mBI-EFS Favorable/Unfavorable Outcomes following TMT.
View article: Supplementary Figure S2 from Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer
Supplementary Figure S2 from Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer Open
Comutation plot of MIBC TCGA genes.
View article: Supplementary Figure S11 from Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer
Supplementary Figure S11 from Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer Open
Distribution of ERCC2 mutations present in TCGA Bladder.
View article: Supplementary Figure S11 from Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer
Supplementary Figure S11 from Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer Open
Distribution of ERCC2 mutations present in TCGA Bladder.
View article: Supplementary Figure S6 from Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer
Supplementary Figure S6 from Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer Open
Association of gene signature scores and TP53-mutated tumors.
View article: Supplementary Figure S8 from Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer
Supplementary Figure S8 from Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer Open
Tumor Mutational Burden between Patients with Favorable (F) versus Unfavorable (UF) mBI-EFS Outcomes following TMT.
View article: Supplementary Figure S15 from Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer
Supplementary Figure S15 from Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer Open
GSC Subtype Signatures by ERCC2 mutation.
View article: Supplementary Figure S14 from Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer
Supplementary Figure S14 from Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer Open
Hallmark DNA repair signature score by ERCC2 mutation status.
View article: Supplementary Figure S12 from Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer
Supplementary Figure S12 from Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer Open
DDR Mutations and association with re-modified BI-EFS.
View article: Supplementary Table S2 from Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer
Supplementary Table S2 from Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer Open
Association of Alliance/RETAIN Trial DDR Genes with Clinical Outcomes following TMT
View article: Supplementary Figure S9 from Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer
Supplementary Figure S9 from Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer Open
Association of select DNA Damage Response (DDR) genes and Overall Survival in the TCGA cohort.
View article: Data from Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer
Data from Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer Open
Purpose:There is an urgent need for biomarkers of radiation response in organ-sparing therapies. Bladder preservation with trimodality therapy (TMT), consisting of transurethral tumor resection followed by chemoradiation, is an alternative…
View article: Supplementary Figure S1 from Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer
Supplementary Figure S1 from Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer Open
Sample inclusion and analytic workflow.
View article: Supplementary Table S2 from Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer
Supplementary Table S2 from Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer Open
Association of Alliance/RETAIN Trial DDR Genes with Clinical Outcomes following TMT
View article: Supplementary Table S5 from Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer
Supplementary Table S5 from Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer Open
List of ERCC2 mutations within cohort
View article: Supplementary Figure S13 from Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer
Supplementary Figure S13 from Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer Open
ERCC2 mutations and association with re-modified BI-EFS.
View article: Supplementary Figure S8 from Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer
Supplementary Figure S8 from Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer Open
Tumor Mutational Burden between Patients with Favorable (F) versus Unfavorable (UF) mBI-EFS Outcomes following TMT.
View article: Supplementary Figure S5 from Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer
Supplementary Figure S5 from Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer Open
FGFR3 mutation correlation with FGFR3 gene expression scores.
View article: Supplementary Table S3 from Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer
Supplementary Table S3 from Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer Open
Association of Alliance/RETAIN Trial DDR Genes with Loss-of-function as per OncoKB with Clinical Outcomes following TMT
View article: Supplementary Figure S5 from Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer
Supplementary Figure S5 from Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer Open
FGFR3 mutation correlation with FGFR3 gene expression scores.
View article: Supplementary Figure S10 from Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer
Supplementary Figure S10 from Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer Open
Comparison of Patient Eligibility based on select DNA Damage Response (DDR) gene mutations for the Alliance A031701, RETAIN-BLADDER Trials and by mBI-EFS Favorable/Unfavorable Outcomes following TMT.
View article: Supplementary Figure S4 from Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer
Supplementary Figure S4 from Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer Open
Comparison of TCGA subtypes between our cohort and the TCGA Bladder cohort.
View article: Supplementary Figure S6 from Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer
Supplementary Figure S6 from Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer Open
Association of gene signature scores and TP53-mutated tumors.